List of Figures
Figure 1: Epidemiology Patterns for Atopic Dermatitis (Million), 2015–2022 16
Figure 2: Epidemiology Patterns for Acne Vulgaris (Million), 2015–2022 17
Figure 3: Epidemiology Patterns for Psoriasis (Million), 2015–2022 18
Figure 4: Dermatology, Global, Key Marketed Products and Approved Indications, 2015 25
Figure 5: Dermatology Therapeutics Market, Global, Annual Revenue for Humira ($bn), 2006–2022 27
Figure 6: Dermatology Therapeutics Market, Global, Annual Revenue for Remicade ($bn), 2006–2022 28
Figure 7: Dermatology Therapeutics Market, Global, Annual Revenue for Enbrel ($bn), 2006-2022 30
Figure 8: Dermatology Therapeutics Market, Global, Annual Revenue for Stelara ($bn), 2010–2022 31
Figure 9: Dermatology Therapeutics Market, Global, Annual Revenue for Neoral ($m), 2006–2022 33
Figure 10: Dermatology Therapeutics Market, Global, Annual Revenue for Protopic ($m), 2006–2022 34
Figure 11: Dermatology Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2016 39
Figure 12: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Stage of Development, Molecule Type and Program Type, 2016 41
Figure 13: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Stage of Development, 2016 42
Figure 14: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecule Type, 2016 43
Figure 15: Dermatology Therapeutics Market, Global, Pipeline for Dermatology by Molecular Target, 2016 44
Figure 16: Dermatology Therapeutics Market, Global, Pipeline for Key Dermatology Indications by Molecular Target, 2016 45
Figure 17: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development (%), 2006–2016 46
Figure 18: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Indication (%), 2006–2016 47
Figure 19: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006–2016 48
Figure 20: Dermatology Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006–2016 49
Figure 21: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development (months), 2006–2016 50
Figure 22: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Indication (months), 2006–2016 51
Figure 23: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecule Type (months), 2006–2016 52
Figure 24: Dermatology Therapeutics Market, Global, Clinical Trial Duration by Stage of Development and Molecular Target (months), 2006–2016 53
Figure 25: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development (patients), 2006–2016 54
Figure 26: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Indication (participants), 2006–2016 55
Figure 27: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecule Type (participants), 2006–2016 56
Figure 28: Dermatology Therapeutics Market, Global, Clinical Trial Size by Stage of Development and Molecular Target (participants), 2006–2016 57
Figure 29: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development (months), 2006–2016 58
Figure 30: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Indication (participants), 2006–2016 59
Figure 31: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecule Type (participants), 2006–2016 60
Figure 32: Dermatology Therapeutics Market, Global, Clinical Program Size by Stage of Development and Molecular Target (participants), 2006–2016 61
Figure 33: Dermatology Global, Market Size ($bn), 2015–2022 62
Figure 34: Dermatology Global, Annual Revenue Forecast for Key Products ($bn), 2015–2022 64
Figure 35: Dermatology, Global, Annual Revenue Forecast for Tumor Necrosis Factor-Alpha Inhibitors ($bn), 2015–2022 67
Figure 36: Dermatology, Global, Annual Revenue Forecast for Interleukin Inhibitors ($bn), 2015–2022 68
Figure 37: Dermatology, Global, Annual Revenue Forecast for Calcineurin Inhibitors ($bn), 2015–2022 69
Figure 38: Dermatology, Global, Annual Revenue Forecast for Glucocorticosteroids ($m), 2015–2022 70
Figure 39: Dermatology, Global, Annual Revenue Forecast for Phosphodiesterase 4 inhibitors ($bn), 2015–2022 71
Figure 40: Dermatology Therapeutics Market, Global, Forecast Market Share by Company (%), 2015–2022 74
Figure 41: Dermatology, Global, Companies by Compound Annual Growth Rate (%), 2015–2022 75
Figure 42: Dermatology, Global, Revenues by Product Type, 2015–2022 76
Figure 43: Dermatology, Global, Johnson & Johnson Annual Revenue Forecast ($bn), 2015–2022 77
Figure 44: Dermatology, Global, AbbVie Annual Revenue Forecast ($bn), 2015–2022 78
Figure 45: Dermatology, Global, Amgen Annual Revenue Forecast ($bn), 2015–2022 79
Figure 46: Dermatology, Global, Novartis Annual Revenue Forecast ($bn), 2015–2022 80
Figure 47: Dermatology, Global, Roche Annual Revenue Forecast ($bn), 2015–2022 81
Figure 48: Dermatology, Global, Merck Annual Revenue Forecast ($bn), 2015–2022 82
Figure 49: Dermatology Therapeutics Market, Global, Revenue Forecast for ABP-501 ($m), 2015–2022 83
Figure 50: Dermatology Therapeutics Market, Global, Revenue Forecast for ixekizumab ($m), 2016–2022 84
Figure 51: Dermatology Therapeutics Market, Global, Revenue Forecast for dupilumab ($m), 2016–2022 85
Figure 52: Dermatology Therapeutics Market, Global, Revenue Forecast for AN-2728 ($m), 2016–2022 86
Figure 53: Dermatology Therapeutics Market, Global, Revenue Forecast for AMG-827 ($m), 2016–2022 87
Figure 54: Dermatology Therapeutics Market, Global, Revenue Forecast for guselkumab ($m), 2016–2022 88
Figure 55: Dermatology Therapeutics Market, Global, Cluster by Growth and Market Share, 2015–2022 90
Figure 56: Dermatology, Global, Companies by Type, 2016 92
Figure 57: Dermatology, Global, Pipeline, High-Activity and Late-Stage Developers by Level of Dermatology Specialization, 2016 93
Figure 58: Dermatology, Global, Proportion of Total Company Revenue Attributed to Dermatology, 2015–2022 94
Figure 59: Dermatology, Global, Licensing Deals, 2006–2016 96
Figure 60: Dermatology, Global, Licensing Deals by Indication, 2006–2016 97
Figure 61: Dermatology, Global, Licensing Deals, 2006–2016 98
Figure 62: Dermatology, Global, Licensing Deals by Molecule Type and Mechanism of Action, 2006–2016 99
Figure 63: Dermatology, Global, Co-development Deals, 2006–2016 101
Figure 64: Dermatology, Global, Co-development Deals by Indication, 2006–2016 102
Figure 65: Dermatology, Global, Co-development Deals, 2006–2016 103
Figure 66: Dermatology, Global, Co-development Deals by Molecule Type and Mechanism of Action, 2006–2016 104